Physician profile
Yu Wang
NPI 1659720993
$2,269.98
in general payments reported to CMS, 2019-2025
19 companies · $573 in 2025
The $573 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $448 · 2022: $578 · 2023: $411 · 2024: $259 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,243.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,166.53 | 2021-2025 | |
| Janssen Biotech, INC. | $136.18 | 2022-2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $126.11 | 2021-2025 | Entyvio, Gattex |
| Braintree Laboratories, INC. | $103.27 | 2021-2024 | Suflave, Sutab |
| Nestle Healthcare Nutrition INC. | $100.94 | 2021-2023 | |
| Novo Nordisk INC | $97.32 | 2025 | Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.68 | 2021-2023 | Xifaxan |
| Qol Medical, LLC | $75.26 | 2023-2025 | Sucraid |
| Daiichi Sankyo INC. | $65.86 | 2021-2022 | |
| Pfizer INC. | $65.45 | 2025 | |
| Intercept Pharmaceuticals, INC. | $61.10 | 2021-2022 | |
| Genzyme Corporation | $51.86 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $30.72 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $24.69 | 2023 | Dupixent |
| Gilead Sciences, INC. | $18.81 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $15.86 | 2025 | Ibsrela |
| Fresenius Kabi USA, LLC | $15.61 | 2023 | Idacio |
| Phathom Pharmaceuticals, INC. | $14.47 | 2025 | Voquezna |
| Organon LLC | $9.26 | 2023 | Renflexis, Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yu Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.